Contribution to the development of inhibitors of 17β-hydroxysteroid dehydrogenase types 1 and 7: Key tools for studying and treating estrogen-dependent diseases

Journal of Steroid Biochemistry and Molecular Biology

Volumn 125, Issue 1-2, 2011, Pages 83-94

  Poirier, Donald ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

17 HSD; Cancer; Enzyme; Estrogen; Hydroxysteroid dehydrogenase; Inhibitor; Steroid

Indexed keywords

17BETA (N,N DIETHYLCARBAMOYL) 4 METHYL 4 AZA 5ALPHA ANDROSTAN 3 ONE; AROMATASE INHIBITOR; PRASTERONE; TESTOSTERONE 17BETA DEHYDROGENASE;

DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; ESTROGEN ACTIVITY; ESTROGEN DEFICIENCY; HUMAN; IC 50; NONHUMAN; OXIDATION REDUCTION REACTION; REVIEW; STRUCTURE ACTIVITY RELATION;

17-HYDROXYSTEROID DEHYDROGENASES; ANDROGENS; ANIMALS; ENZYME INHIBITORS; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; ISOENZYMES; MALE; MOLECULAR STRUCTURE; NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN;

EID: 79957737745     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.12.007     Document Type: Review

References (95)

1. A.H. Payne, and D.B. Hales Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones Endocr. Rev. 25 2004 947 970 (Pubitemid 39657774)
2. T.M. Penning Molecular endocrinology of hydroxysteroid dehydrogenases Endocr. Rev. 18 1997 281 305 (Pubitemid 27246879)
3. T.M. Penning, and J.W. Ricigliano Mechanism based inhibition of hydroxysteroid dehydrogenases J. Enzyme Inhib. 5 1991 165 198
4. F. Labrie, V. Luu-The, S.X. Lin, J. Simard, and C. Labrie Role of 17β-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues Trends Endocr. Metab. 11 2000 421 427
5. F. Labrie, V. Luu-The, S.X. Lin, C. Labrie, J. Simard, R. Breton, and A. Bélanger The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology Steroids 62 1997 148 158 (Pubitemid 27066999)
6. V. Luu-The, and F. Labrie The intracrine sex steroid biosynthesis pathways L. Martini, Progress in Brain Research vol. 181 2010 Elsevier 177 192 (Chapter 10)
7. G. Moeller, and J. Adamski Integrated view on 17beta-hydroxysteroid dehydrogenases Mol. Cell. Endocrinol. 301 2009 7 19
8. G. Moeller, and J. Adamski Multifunctionality of human 17β-hydroxysteroid dehydrogenases Mol. Cell. Endocrinol. 248 2006 47 55
9. P. Lukacik, K.L. Kavanagh, and U. Oppermann Structure and function of human 17β-hydroxysteroid dehydrogenases Mol. Cell. Endocrinol. 248 2006 61 71
10. V. Luu-The Analysis and characteristics of multiple types of human 17β-hydroxysteroid dehydrogenase J. Steroid Biochem. Mol. Biol. 76 2001 143 151 (Pubitemid 32510676)
11. K.J. Ryan, and L.L. Engel The interconversion of estrone and estradiol by human tissue slices Endocrinology 52 1953 287 291
12. D. Poirier Inhibitors of 17β-hydroxysteroid dehydrogenase: a patent review Expert Opin. Ther. Patents 20 2010 1123 1145
13. D. Poirier Advances in development of inhibitors of 17β- hydroxysteroid dehydrogenases Anti-Cancer Agents Med. Chem. 9 2009 642 660
14. S. Nagasaki, Y. Miki, J.I. Akahira, T. Suzuki, and H. Sasano 17β-Hydroxysteroid dehydrogenases in human breast cancer Ann. N. Y. Acad. Sci. 1155 2009 25 32
15. M. Meier, G. Möller, and J. Adamski Perspectives in understanding the role of human 17β-hydroxysteroid dehydrogenases in health and disease Ann. N. Y. Acad. Sci. 1155 2009 15 24
16. P. Brozic, T. Lanisnik-Risner, and S. Gobec Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 Curr. Med. Chem. 15 2008 137 150
17. J.M. Day, H.J. Tutill, A. Purohit, and M.J. Reed Design and validation of specific inhibitors of 17β-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis Endocr. Relat. Cancer 15 2008 665 692
18. M.L. Mohler, R. Narayanan, Y. He, D.D. Miler, and J.T. Dalton Hydroxysteroid dehydrogenase (17β-HSD3, 17β-HSD5 and 3α-HSD3) inhibitors: extragonadal regulation of intracellular sex steroid hormone levels Recent Pat. Endocr. Metab. Immune Drug Discov. 1 2007 103 108
19. J.R. Pasqualini The selective estrogen enzyme modulators in breast cancer: a review Biochim. Biophys. Acta 1654 2004 123 143 (Pubitemid 38681205)
20. D. Poirier Inhibitors of 17β-hydroxysteroid dehydrogenases Curr. Med. Chem. 10 2003 453 477
21. P. Vihko, A. Herrala, P. Harkonen, V. Isomaa, H. Haija, R. Kurkela, and A. Pulkka Control of cell proliferation by steroids: the role of 17β-HSDs Mol. Cell. Endocrinol. 248 2006 141 148
22. P. Vihko, P. Harkonen, P. Soronen, S. Torn, A. Herrala, R. Kurkela, A. Pulkka, O. Oduwole, and V. Isomaa 17β-Hydroxysteroid dehydrogenases - their role in pathophysiology Mol. Cell. Endocrinol. 215 2004 83 88 (Pubitemid 38333245)
23. F. Labrie, V. Luu-The, A. Bélanger, S.X. Lin, J. Simard, G. Pelletier, and C. Labrie Is dehydroepiandrosterone a hormone? J. Endocrinol. 187 2005 169 196 (Pubitemid 41685178)
24. F. Labrie, V. Luu-The, C. Labrie, A. Bélanger, J. Simard, S.X. Lin, and G. Pelletier Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone Endocr. Rev. 24 2003 152 182 (Pubitemid 36515283)
25. H.J. Smith, P.J. Nicholls, C. Simons, and R. Le Lain Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers Exp. Opin. Ther. Patents 11 2001 789 824 (Pubitemid 32427704)
26. R. White, and M.G. Parker Molecular mechanisms of steroid hormone action Endocr. Relat. Cancer 5 1998 1 14 (Pubitemid 28168185)
27. G.M. Anstead, K.E. Carlson, and J.A. Katzenellenbogen The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site Steroids 62 1997 268 303 (Pubitemid 27114399)
28. E. von Angerer The estrogen receptor as a target for rational drug design Molecular Biology Intelligence Unit 1995 R.G. Landes Company Austin, TX
29. D. Poirier New cancer drugs targeting the biosynthesis of estrogens and androgens Drug Devel. Res. 69 2008 304 318
30. J. Simard, A. Vincent, R. Duchesne, and F. Labrie Full oestrogenic activity of C19-delta 5 adrenal steroids in rat pituitary lactotrophs and somatotrophs Mol. Cell. Endocrinol. 55 1988 233 242 (Pubitemid 18055213)
31. S. Auger, Y. Mérand, J.D. Pelletier, D. Poirier, and F. Labrie Synthesis and biological activities of thioether derivatives related to the antiestrogens tamoxifen and ICI 164384 J. Steroid Biochem. Mol. Biol. 52 1995 547 565
32. D. Poirier, P. Dionne, and S. Auger A 6β-(thiaheptanamide) derivative of estradiol as inhibitor of 17β-hydroxysteroid dehydrogenase type 1 J. Steroid Biochem. Mol. Biol. 64 1998 83 90 (Pubitemid 28132850)
33. M.R. Tremblay, R.P. Boivin, V. Luu-The, and D. Poirier Inhibitors of type 1 17β-hydroxysteroid dehydrogenase with reduced estrogenic activity: modifications of the positions 3 and 6 of estradiol J. Enzyme Inhib. Med. Chem. 20 2005 153 163 (Pubitemid 40645506)
34. C. Cadot, Y. Laplante, F. Kamal, V. Luu-The, and D. Poirier C6-(NN-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17β-hydroxysteroid dehydrogenase: chemical synthesis and biological evaluation Bioorg. Med. Chem. 15 2007 714 726 (Pubitemid 44880729)
35. K.M. Sam, R.P. Boivin, S. Auger, and D. Poirier 16α-Propyl derivatives of estradiol as inhibitors of 17β-hydroxysteroid dehydrogenase type 1 Bioorg. Med. Chem. Lett. 4 1994 2129 2132 (Pubitemid 24283139)
36. K.M. Sam, R.P. Boivin, M.R. Tremblay, S. Auger, and D. Poirier C16 and C17 derivatives of estradiol as inhibitors of 17β-hydroxysteroid dehydrogenase type 1: chemical synthesis and structure-activity relationships Drug Des. Discov. 15 1998 157 180 (Pubitemid 28301999)
37. V. Luu-The, Y. Zhang, D. Poirier, and F. Labrie Characteristics of human types 1, 2, and 3 17β-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition J. Steroid Biochem. Mol. Biol. 55 1995 581 587 (Pubitemid 26019342)
38. C.H. Blomquist, B.S. Leung, C. Beaudoin, D. Poirier, and Y. Tremblay Intracellular regulation of 17β-hydroxysteroid dehydrogenase type 2 catalytic activity in A431 cells J. Endocrinol. 153 1997 453 464 (Pubitemid 27261256)
39. M.R. Tremblay, S. Auger, and D. Poirier Synthesis of 16α- (bromoalkyl)-estradiols having inhibitory effect on human placental estradiol 17β-hydroxysteroid dehydrogenase (17β-HSD type 1) Bioorg. Med. Chem. 3 1995 505 523
40. M.R. Tremblay, and D. Poirier Overview of a rational approach to design type I 17β-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation J. Steroid Biochem. Mol. Biol. 66 1998 179 191 (Pubitemid 28401692)
41. M.R. Tremblay, S. Auger, and D. Poirier A convenient synthetic method for alpha-alkylation of steroidal 17-ketone: preparation of 16β-(THPO-heptyl)- estradiol Synth. Commun. 25 1995 2483 2495
42. J.D. Pelletier, F. Labrie, and D. Poirier N-butyl, N-methyl 11-[3′,17'β-(dihydroxy)-1′,3′,5′(10′) -estratrien-16′α-yl]-9(R/S)-bromo undecanamide: synthesis and 17β-HSD inhibiting, estrogenic and antiestrogenic activities Steroids 59 1994 536 547
43. J.D. Pelletier, and D. Poirier Synthesis and evaluation of estradiol derivatives with 16α-(bromoalkylamide), 16α-(bromoalkyl) or 16α-(bromoalkynyl) side chain as inhibitors of 17β-hydroxysteroid dehydrogenase type 1 without estrogenic activity Bioorg. Med. Chem. 4 1996 1617 1628 (Pubitemid 26361866)
44. M.R. Tremblay, and D. Poirier Synthesis of 16-[carbamoyl (bromomethyl)alkyl]-estradiol: a potential dual-action inhibitor designed to blockade estrogen action and biosynthesis J. Chem. Soc. Perkin Trans. I 1996 2765 2771
45. F. Rouillard, J. Lefebvre, M.A. Fournier, and D. Poirier Chemical synthesis, 17β-hydroxysteroid dehydrogenase inhibitory activity and assessment of in vitro and in vivo estrogenic activities of estradiol derivatives Open Enzyme Inhib. J. 1 2008 61 71
46. S.X. Lin, M. Baltzinger, and P. Remy Fast kinetic study of yeast phenylalanyl-tRNA synthetase: an efficient discrimination between tyrosine and phenylalanine at the level of the aminoacyladenylate-enzyme complex Biochemistry 22 1983 681 689
47. + J. Mol. Biol. 234 1993 242 244 (Pubitemid 23337979)
48. D. Ghosh, V.Z. Pletnev, D.W. Zhu, Z. Wawrzak, W.L. Duax, W. Pangborn, F. Labrie, and S.X. Lin Structure of human estrogenic 17β-hydrosteroid dehydrogenase at 2.20 resolution Structure 3 1995 503 513
49. A. Azzi, P. Rehse, D.W. Zhu, R.L. Campbell, F. Labrie, and S.X. Lin Crystal structure of human estrogenic 17β-hydroxysteroid dehydrogenase complexed with 17β-estradiol Nat. Struct. Biol. 3 1996 665 668 (Pubitemid 26260054)
50. D. Poirier, R.P. Boivin, M. Bérubé, and S.X. Lin Synthesis of a first estradiol-adenosine hybrid compound Synth. Commun. 33 2003 3183 3192 (Pubitemid 37093354)
51. D. Poirier, R.P. Boivin, M.R. Tremblay, M. Bérubé, W. Qiu, and S.X. Lin Estradiol-adenosine hybrid compounds designed to inhibit type 1 17β-hydroxysteroid dehydrogenase J. Med. Chem. 48 2005 8134 8147 (Pubitemid 43032522)
52. W. Qiu, R.L. Campbell, A. Gangloff, P. Dupuis, R.P. Boivin, M.R. Tremblay, D. Poirier, and S.X. Lin A concerted, rational design of type 1 17β-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity Faseb J. 16 2002 1829 1831
53. M. Bérubé, and D.D. Poirier Improved synthesis of EM-1745, preparation of its C17-ketone analogue and comparison of their inhibitory potency on 17β-hydroxysteroid dehydrogenase type 1 J. Enzyme Inhib. Med. Chem. 24 2009 832 843
54. D. Fournier, D. Poirier, M. Mazumdar, and S.X. Lin Design and synthesis of bisubstrate inhibitors of type 1 17β-hydroxysteroid dehydrogenase: overview and perspectives Eur. J. Med. Chem. 43 2008 2298 2306
55. M. Bérubé, and D. Poirier Synthesis of simplified hybrid inhibitors of type 1 17β-hydroxysteroid dehydrogenase via the cross-methathesis and the Sonogashira coupling reactions Org. Lett. 6 2004 3127 3130 (Pubitemid 39233136)
56. M. Bérubé, and D. Poirier Design, chemical synthesis and in vitro biological evaluation of simplified estradiol-adenosine hybrids as inhibitors of 17β-hydroxysteroid dehydrogenase type 1 Can. J. Chem. 87 2009 1180 1199
57. M.R. Tremblay, S.X. Lin, and D. Poirier Chemical synthesis of 16β-propylaminoacyl derivatives of estradiol and their inhibitory potency on type 1 17β-hydroxysteroid dehydrogenase and binding affinity on steroid receptors Steroids 66 2001 821 831 (Pubitemid 32884309)
58. M.R. Tremblay, and D. Poirier Solid-phase synthesis of phenolic steroids: from optimization studies to a convenient procedure for combinatorial synthesis of biologically relevant estradiol derivatives J. Comb. Chem. 2 2000 48 65
59. R. Maltais, M.R. Tremblay, and D. Poirier Solid-phase synthesis of hydroxysteroid derivatives using the diethylsilyloxy linker J. Comb. Chem. 2 2000 604 614
60. L.C. Ciobanu, R. Maltais, and D. Poirier The sulfamate functional group as a new anchor for solid-phase organic synthesis Org. Lett. 2 2000 445 448
61. P.A. Foster, M.J. Reed, and A. Purohit Recent developments of steroid sulfatase inhibitors as anti-cancer agents Anti-Cancer Agents Med. Chem. 8 2008 732 738
62. K. Aidoo-Gyamfi, T. Cartledge, K. Shah, and S. Ahmed Estrone sulfatase and its inhibitors Anti-Cancer Agents Med. Chem. 9 2009 599 612
63. J.Y. Winum, A. Scozzafava, J.L. Montero, and C. Supuran Therapeutic applications of sulfamates Expert Opin. Ther. Patents 14 2004 1273 1308 (Pubitemid 39242726)
64. D. Poirier, and R. Maltais Solid-phase organic synthesis (SPOS) of modulators of estrogenic and androgenic action Mini-Rev. Med. Chem. 6 2006 37 52
65. D. Poirier, L.C. Ciobanu, and M. Bérubé A multidetachable sulfamate linker and solid-phase strategy used to generate libraries of sulfamate and phenol derivatives Bioorg. Med. Chem. Lett. 12 2002 2833 2838 (Pubitemid 35266744)
66. D. Poirier, M. Bérubé, and D. Fournier The sulfamate multidetachable linker: an efficient tool for solid-phase synthesis of steroid sulfatase and 17β-HSDs enzyme inhibitors R. Epton, Innovation and Perspectives in Solid Phase Synthesis & Combinatorial Libraries (Peptides, Proteins and Nucleic Acids Small Molecule Organic Chemical Diversity) 2004 Mayflower Worldwide Kingswinford UK 281 285
67. D. Fournier, P.A. Breuil, and D. Poirier Synthesis of aryl sulfamate and phenol small peptide derivatives using a multidetachable sulfamate linker strategy Adv. Exp. Med. Biol. 611 2009 219 220
68. L.C. Ciobanu, and D. Poirier Synthesis of libraries of 16β-aminopropyl estradiol derivatives for targeting two key steroidogenic enzymes ChemMedChem 1 2006 1249 1259 (Pubitemid 44786931)
69. M. Bérubé, F. Delagoutte, and D. Poirier Preparation of libraries of 16β-estradiol derivatives as bisubstrate inhibitors of type 1 17β-hydroxysteroid dehydrogenase using the multidetachable sulfamate linker Molecules 15 2010 1590 1631
70. D. Poirier, H.J. Chang, A. Azzi, R.P. Boivin, and S.X. Lin Estrone and estradiol C-16 derivatives as inhibitors of type 1 17β-hydroxysteroid dehydrogenase Mol. Cell. Endocrinol. 248 2006 236 238
71. J. Messinger, L. Hirvela, B. Husen, L. Kangas, P. Koskimies, O. Pentikainen, P. Saarenketo, and H. Thole New inhibitors of 17β- hydroxysteroid dehydrogenase type 1 Mol. Cell. Endocrinol. 248 2006 192 198
72. C. Labrie, C. Martel, J.M. Dufour, C. Lévesque, Y. Mérand, and F. Labrie Novel compounds inhibit estrogen formation and action Cancer Res. 52 1992 610 615
73. N. Vicker, H.R. Lawrence, G.M. Allan, C. Bubert, A. Smith, H.J. Tutill, A. Purohit, J.M. Day, M.F. Mahon, M.J. Reed, and B.V.L. Potter Focused libraries of 16-substituted estrone derivatives and modified E-ring steroids: inhibitors of 17β-hydroxysteroid dehydrogenase type 1 ChemMedChem 1 2006 464 481
74. + breast cancer cell proliferation induced by estrone Bioorg. Med. Chem. 16 2008 1849 1860 (Pubitemid 351226579)
75. M. Mazumdar, D. Fournier, D.W. Zhu, C. Cadot, D. Poirier, and S.X. Lin Binary and ternary crystal structure analyses of a novel inhibitor with 17β-HSD type 1: a lead compound for breast cancer therapy Biochem. J. 424 2009 357 366
76. J.Z. Jin, and S.X.S.X. Lin Human estrogenic 17β- hydroxysteroidehydrogenase: predominance of estrone reduction and its induction by NADPH Biochem. Biophys. Res. Commun. 259 1999 489 493
77. A. Krazeisen, R. Breitling, K. Imai, S. Fritz, G. Möller, and J. Adamski Determination of cDNA, gene structure and chromosomal localization of the novel human 17β-hydroxysteroid dehydrogenase type 7 FEBS Lett. 460 1999 373 379 (Pubitemid 29495972)
78. R. Breitling, A. Krazeisen, G. Möller, and J. Adamski 17β-Hydroxysteroid dehydrogenase type 7 - an ancient 3-ketosteroid reductase of cholesterogenesis Mol. Cell. Endocrinol. 171 2001 199 204 (Pubitemid 32098215)
79. S. Torn, P. Nokelainen, R. Kurkela, A. Pulkka, M. Menjivar, S. Ghosh, M. Coca-Prados, H. Peltoketo, V. Isomaa, and P. Vihko Production, purification, and functional analysis of recombinant human and mouse 17β-hydroxysteroid dehydrogenase type 7 Biochem. Biophys. Res. Commun. 305 2003 37 45 (Pubitemid 36535406)
80. D. Song, G. Liu, V. Luu-The, D. Zhao, L. Wang, H. Zhang, G. Xueling, S. Li, L. Désy, F. Labrie, and G. Pelletier Expression of aromatase and 17β-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study J. Steroid Biochem. Mol. Biol. 101 2006 136 144 (Pubitemid 44311483)
81. P. Picciarelli-Lima, A.G. Oliveira, A.M. Reis, E. Kalapothakis, G.A.B. Mahecha, R.A. Hess, and C. Oliveira Effects of 3-beta-diol, an androgen metabolite with intrinsic estrogen-like effects, in modulating the aquaporin-9 expression in the rat efferent ductules Reprod. Biol. Endocrinol. 4 2006 51
82. Z. Marijanovic, D. Laubner, G. Moller, C. Gege, B. Husen, J. Adamski, and R. Breitling Closing the gap: identification of human 3-ketosteroid reductase, the last unknown enzyme of mammalian cholesterol biosynthesis Mol. Endocrinol. 17 2003 1715 1725 (Pubitemid 37072289)
83. T. Ohnesorg, and J. Adamski Promoter analyses of human and mouse 17beta-hydroxysteroid dehydrogenase type 7 J. Steroid Biochem. Mol. Biol. 94 2005 259 261 (Pubitemid 40614539)
84. T. Ohnesorg, B. Keller, M. Hrabé de Angelis, and J. Adamski Transcriptional regulation of human and murine 17β-hydroxysteroid dehydrogenase type-7 confers its participation in cholesterol biosynthesis J. Mol. Endocrinol. 37 2006 185 197 (Pubitemid 44288616)
85. E. Bellavance, V. Luu-The, and D. Poirier First inhibitors of the steroidogenic enzyme type 7 17β-hydroxysteroid dehydrogenase Lett. Drug Design Discov. 1 2004 194 197
86. E. Bellavance, V. Luu-The, and D. Poirier Potent and selective inhibitors of 17β-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone J. Med. Chem. 52 2009 7488 7502
87. P. Bydal, V. Luu-The, F. Labrie, and D. Poirier Steroidal lactones as inhibitors of 17β-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities Eur. J. Med. Chem. 44 2009 632 644
88. E. Bellavance, Étude structure activité menant au développement d'inhibiteurs sélectifs de la 17β- hydroxystéroïde déshydrogénase type 7. M.Sc. Thesis. Université Laval, 2004, pp. 112-123.
89. Y. Laplante, C. Rancourt, and D. Poirier Relative involvement of three 17β-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors Mol. Cell. Endocrinol. 301 2009 146 153
90. J.C. Chura, H.S. Ryu, D. Poirier, Y. Tremblay, D.C. Brooker, C.H. Bloomquist, and P.A. Argena Steroid converting enzymes in human ovarian carcinomas Mol. Cell. Endocrinol. 301 2009 51 58
91. M. Samson, F. Labrie, and V. Luu-The Specific estradiol biosynthesis pathway in choriocarcinoma (JEG-3) cell line J. Steroid Biochem. Mol. Biol. 116 2009 154 159
92. M.A. Fournier, and D. Poirier Estrogen formation in endometrial and cervix cancer cell lines: involvement of aromatase, steroid sulfatase and 17β-hydroxysteroid dehydrogenases (types 1, 5, 7 and 12) Mol. Cell. Endocrinol. 301 2009 142 145
93. K. Mukherjee, V. Syed, and S.M. Ho Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells Oncogene 24 2005 4388 4400 (Pubitemid 40961762)
94. J. Aka, M. Mazumdar, C.Q. Chen, D. Poirier, and S.X. Lin 17β-Hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production Mol. Endocrinol. 24 2010 832 845
95. M. Frotscher, E. Ziegler, S. Marchais-Oberwinkler, P. Kruchten, A. Neugebauer, L. Fetzer, C. Scherer, U. Muller-Vieira, J. Messinger, H. Thole, and R.W. Hartmann Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and quinoline derivatives: potent and selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases J. Med. Chem. 51 2008 2158 2169 (Pubitemid 351503271)